WINTON GROUP Ltd Purchases 329,579 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

WINTON GROUP Ltd raised its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 339.0% in the 4th quarter, Holdings Channel.com reports. The fund owned 426,814 shares of the biopharmaceutical company’s stock after buying an additional 329,579 shares during the period. WINTON GROUP Ltd’s holdings in Dynavax Technologies were worth $5,450,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DVAX. Fox Run Management L.L.C. bought a new position in Dynavax Technologies in the fourth quarter valued at $883,000. KLP Kapitalforvaltning AS acquired a new position in shares of Dynavax Technologies during the 4th quarter worth about $358,000. American Century Companies Inc. grew its holdings in shares of Dynavax Technologies by 11.1% in the 4th quarter. American Century Companies Inc. now owns 261,802 shares of the biopharmaceutical company’s stock valued at $3,343,000 after acquiring an additional 26,135 shares in the last quarter. Teacher Retirement System of Texas raised its holdings in Dynavax Technologies by 12.2% during the fourth quarter. Teacher Retirement System of Texas now owns 34,979 shares of the biopharmaceutical company’s stock worth $447,000 after acquiring an additional 3,797 shares in the last quarter. Finally, Intech Investment Management LLC boosted its position in Dynavax Technologies by 43.3% during the fourth quarter. Intech Investment Management LLC now owns 53,566 shares of the biopharmaceutical company’s stock valued at $684,000 after purchasing an additional 16,186 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Stock Down 2.9 %

DVAX opened at $13.58 on Thursday. The stock’s fifty day simple moving average is $13.29 and its 200 day simple moving average is $12.46. Dynavax Technologies Co. has a 1-year low of $9.74 and a 1-year high of $14.63. The stock has a market cap of $1.68 billion, a PE ratio of 75.44 and a beta of 1.23. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting the consensus estimate of $0.05. The company had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. As a group, research analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DVAX. William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. The Goldman Sachs Group cut shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and cut their price target for the company from $15.00 to $12.00 in a research note on Tuesday, February 11th. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, February 24th. Finally, HC Wainwright reiterated a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.